Role of FDG PET-CT in recurrent renal cell carcinoma

Nucl Med Commun. 2010 Oct;31(10):844-50. doi: 10.1097/MNM.0b013e32833d6882.

Abstract

Aim: To determine the efficacy of positron emission tomography-computed tomography using F-18 fluoro-deoxy-glucose (F-18 FDG PET-CT) in diagnosing the recurrence of renal cell carcinoma (RCC) in patients treated earlier with partial or radical nephrectomy.

Methods: We assessed 63 patients with suspected recurrent RCC after nephrectomy. PET-CT findings were interpreted as positive if the focal area of FDG uptake in the abdomen or outside the abdomen was more than the surrounding background tissue. The final diagnosis of the recurrence of RCC was based on histological examination and/or clinical follow-up and conventional imaging modalities.

Results: A total of 103 PET-CT studies were done in these 63 patients, of which 63 studies were true positive, 30 studies were true negative, seven studies were false negative and remaining three studies were false positive. In 63 true-positive scans, PET-CT showed 109 lesions. Of these, 28 lesions were in the lungs, 21 lesions were at a locoregional site, 21 were in the bones, 12 in the retroperitoneal lymph nodes and 27 at other sites. The sensitivity, specificity and accuracy of PET-CT were 90, 91 and 90%, respectively.

Conclusion: Our results seem to confirm the useful role of PET-CT in the evaluation of post-surgical recurrence in patients who had undergone radical surgery for RCC.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / surgery
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / surgery
  • Male
  • Middle Aged
  • Nephrectomy
  • Positron-Emission Tomography*
  • Recurrence
  • Retrospective Studies
  • Tomography, X-Ray Computed*
  • Young Adult

Substances

  • Fluorodeoxyglucose F18